Medical Food for the Dietary Management of Metastatic Pancreatic Cancer
Study Details
Study Description
Brief Summary
This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with metastatic pancreatic adenocarcinoma. Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), that are routinely prescribed in combination for metastatic pancreatic cancer as part of their routine care.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Nonessential Amino Acid Restriction (NEAAR) Medical Food This is a single arm study in which all subjects will receive NEAAR medical food. |
Other: NEAAR Medical Food
Standardized non-essential amino acid restricted medical food.
|
Outcome Measures
Primary Outcome Measures
- Demonstrate tolerability of the NEAAR medical food. [Through study completion (average of 6 months)]
The primary endpoint is the rate of the most common Grade 3 and 4 adverse event (AE) related to the NEAAR medical food.
Secondary Outcome Measures
- Overall response rates [Through study completion (average of 6 months)]
Complete response and partial response using RECIST 1.1
- Changes in biomarkers [Through study completion (average of 6 months)]
Absolute and relative change from baseline of disease biomarkers
- Progression-free survival [Through study completion (average of 6 months)]
Duration from radiographic documentation of disease to radiographic documentation of progression or death from any cause
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects presenting with histologically or cytologically confirmed metastatic pancreatic adenocarcinoma diagnosed within 6 weeks prior to screening.
-
Subjects are eligible for and being scheduled to begin standard of care treatment with the gem+nabP regimen.
-
Subjects who are 18 years of age or older.
-
Subjects are capable of giving signed informed consent.
-
Subjects with measurable disease as determined by RECIST 1.1.
-
ECOG Performance Status of ≤ 1.
-
Subject has adequate organ function during screening evaluations defined as all the following:
-
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1500/µL).
-
Platelet count ≥ 100 x 109/L.
-
Hemoglobin ≥ 9 g/dL.
-
Activated partial thromboplastin time /international normalized ratio (aPTT/INR) ≤ 1.5 x upper limit of normal (ULN) unless the subject is on anticoagulants in which case therapeutically acceptable values (as determined by the investigator) meet eligibility requirements.
-
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 × ULN. In the case of known (i.e., radiological or biopsy documented) liver metastasis, serum transferase levels must be ≤ 5 x ULN.
-
Total serum bilirubin ≤ 1.5 x ULN (except for subjects with known Gilbert's Syndrome for which ≤ 3 x ULN is permitted).
-
Serum creatinine < 2.0 x ULN and creatinine clearance ≥ 50 mL/min/1.73m2.
-
Serum albumin ≥ 3.5mg/d or ≥LLN, whichever is lower
-
Subjects must have normal Vitamin D levels or be willing to start Vitamin D supplementation during the NEAAR medical food period.
-
Subjects must have available pancreatic adenocarcinoma tissue samples from a primary or metastatic site that has been biopsied within the last 6 months and provide consent for them to be obtained and analyzed.
-
Subjects must be willing to stop taking any supplements, herbal medicines, or alternative remedies or other prescribed or over the counter supplements for at least 1 week prior to Cycle 1 Day 1 of gem+nabP and through the NEAAR medical food period.
-
Subjects either have normal pancreatic function or are already taking Pancreatic Enzyme Replacement Therapy (PERT). If pancreatic insufficiency status is unknown, subjects must have a fecal elastase test to check for moderate or severe pancreatic insufficiency. Subjects with diagnosed pancreatic insufficiency must take PERT.
Exclusion Criteria:
-
Any prior neoadjuvant or adjuvant therapy for pancreatic cancer within 6 months of screening.
-
Comorbidity risk, that in the discretion of the investigator would make the subject a poor candidate for the NEAAR medical food.
-
Diagnosis of another malignancy within the past 2 years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, or superficial bladder cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment or requires only treatment with luteinizing hormone-releasing hormone agonists or antagonists if initiated at least 30 days prior to beginning the NEAAR medical food).
-
A body mass index (BMI) <18.5 kg/m2 or >40 kg/m2 or, serious or refractive cachexia or anorexia that, in the investigator's opinion, realistically prohibits subjects from having energy or appetite sufficient to reliably engage in a strict medical food regimen for an extended time.
-
Insulin-dependent diabetes.
-
Subjects who must take medications that impact amino acid levels
-
Inability or unwillingness to comply with study and/or follow-up procedures, or medical food modifications described in the protocol.
-
Presence of any significant comorbidity including clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication), myocardial infarction or unstable angina within the 12 months prior to screening, or any major organ failure.
-
Known hypersensitivity, intolerance, or religious restrictions regarding pork or pork-derived products or to any of the components of the medical food modification, gemcitabine or nab-paclitaxel, PERT products (e.g., Pancreaze), or formulary excipients in these products.
-
Untreated clinically significant hyperlipidemia per investigator.
-
Subjects with a condition (including gallbladder disease and/or fatty acid oxidation disorders) where high-fat or fatty food is contraindicated.
-
Any non-cancerous co-existing condition that could elevate CA19-9, CEA, or CA125.
-
Presence of central nervous system or brain metastases that are not controlled under treatment as assessed by the investigator.
-
Presence of any condition (e.g., persistent diarrhea) that renders the subject unable to satisfactorily chew, swallow, digest, or tolerate the majority of foods and liquids of the NEAAR medical food.
-
Taking or needs to take any protein or amino acid containing nutritional supplements (e.g., Ensure®).
-
Women who are, plan to be, or may potentially be pregnant or lactating.
-
Lack of physical integrity of the upper or lower gastrointestinal (GI) tract.
-
Known, existing uncontrolled coagulopathy.
-
Major surgery or significant traumatic injury within 14 days of planned start of NEAAR medical food or the anticipation of the need for a major surgical procedure during the study.
-
Active, clinically significant, uncontrolled bacterial, viral, or fungal infection(s).
-
Known current infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
-
History of confirmed food allergy.
-
Currently enrolled in any other investigational trial or treatment with investigational therapy(ies).
-
Diagnosed with an eating disorder, irritable bowel syndrome (IBS), Crohn's disease, ulcerative colitis, or gluten-sensitive enteropathy.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Arizona Cancer Center | Tucson | Arizona | United States | 85724 |
| 2 | Hoag Memorial Hospital Presbyterian | Newport Beach | California | United States | 92663 |
| 3 | Florida Cancer Specialists | Fort Myers | Florida | United States | 33901 |
| 4 | Louisiana State University Health Sciences Center | Shreveport | Louisiana | United States | 71103 |
| 5 | Atlantic Health | Morristown | New Jersey | United States | 07962 |
| 6 | OU Health - Stephenson Cancer Center | Oklahoma City | Oklahoma | United States | 73104 |
| 7 | Sarah Cannon | Nashville | Tennessee | United States | 37203 |
| 8 | Baylor Scott & White Health | Temple | Texas | United States | 76508 |
| 9 | Medical College of Wisconsin | Milwaukee | Wisconsin | United States | 53226 |
Sponsors and Collaborators
- Faeth Therapeutics
Investigators
- Principal Investigator: Andrew Hendifar, MD, Cedars-Sinai
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NEAAR-001